More Company News

Scancell

Appointment of General Manager and EVP Commercial Operations EUROW
12 Nov 2019Read More

Scancell

NDA acceptance in China for surufatinib in non-pancreatic NET
11 Nov 2019Read More

Scancell

Phase 2b ASTEROID study data in adults with osteogenesis imperfecta
11 Nov 2019Read More

Scancell

Q319 report
07 Nov 2019Read More

Scancell

Clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML to be presented at ASH 2019
07 Nov 2019Read More

Scancell

Bemcentinib meets primary endpoint in first cohort of Phase II NSCLC combination study with Keytruda
06 Nov 2019Read More

Scancell

Approximately 67.4% of offer warrants under Warrant Plan 2019 used for share subscription
06 Nov 2019Read More

Scancell

Phase I with lead CARMA therapy advances to third cohort
24 Oct 2019Read More

Scancell

FDA Fast Track designation for bemcentinib in elderly relapsed AML
22 Oct 2019Read More

Scancell

Share subscription period for Warrant Plan 2019 starts on 22 October
21 Oct 2019Read More

1 2 3 4 … 28
Return to Scancell
© 2019 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).